CRONOS GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | -0.43% |
|
0.00% | +11.48% |
| 06-27 | Cronos Group Inc. Brand Spinach®? Celebrates Summer with New Launches | CI |
| 06-21 | Cronos Group Inc. Elects Murray Garnick as Director | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.1 for the 2024 fiscal year.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +11.48% | 891M | - | ||
| +26.93% | 5.55B | B- | ||
| -33.55% | 3.52B | C+ | ||
| -3.74% | 3.03B | C | ||
| -26.09% | 2.59B | B- | ||
| -10.93% | 2.28B | - | D+ | |
| +41.50% | 1.88B | - | ||
| +41.84% | 1.46B | - | ||
| -12.94% | 1.43B | - | - | |
| +47.62% | 1.42B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRON Stock
- CRON Stock
- Ratings Cronos Group Inc.
